Department of Respiratory Medicine, Affiliated Hospital 2 of Bengbu Medical College, Bengbu, China.
Department of Respiratory Medicine, Affiliated Hospital 2 of Nantong University, Nantong, China.
Can Respir J. 2022 Apr 11;2022:6619331. doi: 10.1155/2022/6619331. eCollection 2022.
The aim of this study was to investigate the expression level of soluble LOX-1 (sLOX-1) in the serum of non-small-cell lung cancer (NSCLC) patients and its correlation with lipid metabolism.
99 inpatients with NSCLC and 81 healthy controls were enrolled in this study. The levels of serum sLOX-1 were compared between the two groups, and the correlation of sLOX-1 with clinicopathological characteristics, blood lipid indices, and carcinoembryonic antigen was analyzed.
Compared with the healthy controls, sLOX-1, low-density lipoprotein, triglyceride, and carcinoembryonic antigen in the patients with NSCLC were significantly higher ( < 0.05), while the expression level of high-density lipoprotein was lower ( < 0.05). The expression level of sLOX-1 in the serum of patients with healthy controls was positively correlated with low-density lipoprotein ( = 0.72, < 0.05). The levels of sLOX-1 and low-density lipoprotein in the serum of patients with NSCLC were closely related to the lymph node metastasis, distant metastasis, and TNM stage ( < 0.05). Compared with a single index, when the sLOX-1 was combined with the CEA, its specificity increased significantly to 97.5% (AUC = 0.995, < 0.01, 95% CI: 0.989-1.000).
sLOX-1 and low-density lipoprotein were overexpressed in the serum of patients with NSCLC, positively correlated, and closely related to the TNM stage and metastasis. This result suggested that lipid metabolic disorders may promote the progression of NSCLC through sLOX-1, which could be a potential serological marker with diagnostic value for NSCLC.
本研究旨在探讨非小细胞肺癌（NSCLC）患者血清中可溶性 LOX-1（sLOX-1）的表达水平及其与脂代谢的关系。
本研究纳入 99 例 NSCLC 住院患者和 81 例健康对照者。比较两组患者血清 sLOX-1 水平，并分析 sLOX-1 与临床病理特征、血脂指标和癌胚抗原的相关性。
与健康对照组相比，NSCLC 患者的 sLOX-1、低密度脂蛋白、甘油三酯和癌胚抗原明显升高（ < 0.05），而高密度脂蛋白表达水平较低（ < 0.05）。健康对照组血清 sLOX-1 表达水平与低密度脂蛋白呈正相关（ = 0.72， < 0.05）。NSCLC 患者血清中 sLOX-1 和低密度脂蛋白水平与淋巴结转移、远处转移和 TNM 分期密切相关（ < 0.05）。与单一指标相比，当 sLOX-1 与 CEA 联合时，其特异性显著增加至 97.5%（AUC = 0.995， < 0.01，95%CI：0.989-1.000）。
sLOX-1 和低密度脂蛋白在 NSCLC 患者血清中过度表达，呈正相关，与 TNM 分期和转移密切相关。这一结果提示，脂代谢紊乱可能通过 sLOX-1 促进 NSCLC 的进展，sLOX-1 可能是一种具有诊断价值的潜在血清标志物。
